Hepatitis B in patients with hematological diseases: An update

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 25

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Sep 8, 2017; 9(25): 1043-1053
Published online Sep 8, 2017. doi: 10.4254/wjh.v9.i25.1043

Table 3 Risk of hepatitis B virus reactivation according to different immunosuppressive drug classes (adapted from[21])

Risk	Drug class
High (> 10%)	B-cell depleting agents
	Anthracycline
	Corticosteroids high dose
Moderate (1%-10%)	TNFα inhibitors
	Cytokine and integrin inhibitors
	Tyrosine kinase inhibitors
	Corticosteroids moderate dose
Low (< 1%)	Corticosteroids low dose
	Traditional immunosuppression (e.g., azathioprine or methotrexate)

Citation: Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol 2017; 9(25): 1043-1053
URL: https://www.wjgnet.com/1948-5182/full/v9/i25/1043.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i25.1043

Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol 2017; 9(25): 1043-1053 [PMID: 28951776 DOI: 10.4254/wjh.v9.i25.1043]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.